+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030- Product Image
Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030- Product Image
Sale

Global Human Papillomavirus Vaccine Market by Disease Indication (Anal Cancer, Cervical Cancer, Genital Warts), Type (Bivalent, Tetravalent & Nonavalent), Distribution Channel - Forecast 2024-2030

  • PDF Icon

    Report

  • 189 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4858029
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Human Papillomavirus Vaccine Market size was estimated at USD 4.30 billion in 2023, USD 4.60 billion in 2024, and is expected to grow at a CAGR of 7.03% to reach USD 6.92 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Human Papillomavirus Vaccine Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Papillomavirus Vaccine Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Human Papillomavirus Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Bavarian Nordic A/S, GlaxoSmithKline PLC, Inovio Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Merck Sharp & Dohme Corp., Mitsubishi Tanabe Pharma Corporation, Novavax, Inc., Pfizer Inc., Wantai BioPharm, and Xenetic Bioscience Inc.

Market Segmentation & Coverage

This research report categorizes the Human Papillomavirus Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Indication
    • Anal Cancer
    • Cervical Cancer
    • Genital Warts
    • Oropharyngeal Cancer
    • Penile Cancer
    • Vaginal Cancer
    • Vulvar Cancer
  • Type
    • Bivalent
    • Tetravalent & Nonavalent
  • Distribution Channel
    • Government Entities
    • Physicians
    • Public & Private Alliances
    • Wholesalers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Human Papillomavirus Vaccine Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Papillomavirus Vaccine Market?
  3. What are the technology trends and regulatory frameworks in the Human Papillomavirus Vaccine Market?
  4. What is the market share of the leading vendors in the Human Papillomavirus Vaccine Market?
  5. Which modes and strategic moves are suitable for entering the Human Papillomavirus Vaccine Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Human Papillomavirus Vaccine Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Human papillomavirus vaccines associated uses for treatment of cancer
5.1.1.2. Widely commended as a sweeping pharmaceutical innovation
5.1.1.3. Funding by the government for R&D of cancer
5.1.2. Restraints
5.1.2.1. Inadequate delivery of infrastructure
5.1.3. Opportunities
5.1.3.1. Growing support for HPV introduction among the global health community
5.1.3.2. Advancements in manufacturing process of HPV vaccines
5.1.4. Challenges
5.1.4.1. Lack of community engagement to generate awareness regarding diagnosis and treatment of HPV
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Human Papillomavirus Vaccine Market, by Disease Indication
6.1. Introduction
6.2. Anal Cancer
6.3. Cervical Cancer
6.4. Genital Warts
6.5. Oropharyngeal Cancer
6.6. Penile Cancer
6.7. Vaginal Cancer
6.8. Vulvar Cancer
7. Human Papillomavirus Vaccine Market, by Type
7.1. Introduction
7.2. Bivalent
7.3. Tetravalent & Nonavalent
8. Human Papillomavirus Vaccine Market, by Distribution Channel
8.1. Introduction
8.2. Government Entities
8.3. Physicians
8.4. Public & Private Alliances
8.5. Wholesalers
9. Americas Human Papillomavirus Vaccine Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Human Papillomavirus Vaccine Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Human Papillomavirus Vaccine Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AstraZeneca PLC
13.1.2. Bavarian Nordic A/S
13.1.3. GlaxoSmithKline PLC
13.1.4. Inovio Pharmaceuticals Inc.
13.1.5. Johnson & Johnson Services, Inc.
13.1.6. Merck Sharp & Dohme Corp.
13.1.7. Mitsubishi Tanabe Pharma Corporation
13.1.8. Novavax, Inc.
13.1.9. Pfizer Inc.
13.1.10. Wantai BioPharm
13.1.11. Xenetic Bioscience Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET RESEARCH PROCESS
FIGURE 2. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2023 VS 2030
FIGURE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET DYNAMICS
FIGURE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. HUMAN PAPILLOMAVIRUS VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 6. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY ANAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GENITAL WARTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY OROPHARYNGEAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PENILE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VAGINAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY VULVAR CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 14. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY BIVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TETRAVALENT & NONAVALENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 17. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY GOVERNMENT ENTITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY PUBLIC & PRIVATE ALLIANCES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 31. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 32. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. CANADA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 34. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 35. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. MEXICO HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 43. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 46. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. AUSTRALIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. CHINA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 52. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 55. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. INDONESIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 58. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. JAPAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. MALAYSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 64. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. PHILIPPINES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 67. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SINGAPORE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 70. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. SOUTH KOREA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 73. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. TAIWAN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. THAILAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 79. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. VIETNAM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. DENMARK HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 89. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. EGYPT HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 92. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FINLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 95. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. FRANCE HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 98. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. GERMANY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ISRAEL HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 104. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. ITALY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 107. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NETHERLANDS HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 110. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NIGERIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 113. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. NORWAY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 116. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. POLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. QATAR HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 125. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SAUDI ARABIA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 128. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH AFRICA HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 130. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 131. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SPAIN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 134. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWEDEN HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 137. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. SWITZERLAND HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. TURKEY HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM HUMAN PAPILLOMAVIRUS VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. HUMAN PAPILLOMAVIRUS VACCINE MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 149. HUMAN PAPILLOMAVIRUS VACCINE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 150. HUMAN PAPILLOMAVIRUS VACCINE MARKET LICENSE & PRICING

Companies Mentioned

  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • GlaxoSmithKline PLC
  • Inovio Pharmaceuticals Inc.
  • Johnson & Johnson Services, Inc.
  • Merck Sharp & Dohme Corp.
  • Mitsubishi Tanabe Pharma Corporation
  • Novavax, Inc.
  • Pfizer Inc.
  • Wantai BioPharm
  • Xenetic Bioscience Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 4.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 6.92 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition - Product Image

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Valence, By Disease Indication, By Distribution Channel, By Region, and By Competition

  • Report
  • 116 Pages
  • Global
From
Global Human Papillomavirus Vaccine Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Human Papillomavirus Vaccine Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 168 Pages
  • Global
From
Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Human Papillomavirus Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 140 Pages
  • Global
From
Human Papillomavirus (HPV) Vaccine Global Market Report 2024 - Product Image

Human Papillomavirus (HPV) Vaccine Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
India Human Papillomavirus Vaccine Market, Competition, Forecast & Opportunities, 2029 - Product Image

India Human Papillomavirus Vaccine Market, Competition, Forecast & Opportunities, 2029

  • Report
  • 90 Pages
  • India
From

About the HPV Vaccine Market

The HPV Vaccine is a type of cancer vaccine used to prevent infection from the human papillomavirus (HPV). HPV is a virus that can cause cervical cancer, as well as other types of cancer. The HPV Vaccine is typically administered to adolescents and young adults, and is recommended by the World Health Organization (WHO) as part of routine immunization programs. The vaccine is available in both a bivalent and quadrivalent form, and is designed to protect against the two most common types of HPV that cause cervical cancer. The HPV Vaccine market is a rapidly growing segment of the cancer vaccine market. It is estimated that the global HPV Vaccine market will reach $4.5 billion by 2027, driven by increasing awareness of the virus and its associated health risks, as well as the availability of the vaccine in many countries. Some of the major companies in the HPV Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and CSL. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.